Moreover, a Phase Ib study (34) suggests that multi-segment blockade of the RAS/RAF/ERK pathway may offer significant antitumor efficacy in patients with advanced and metastatic KRAS or BRAF-mutant non-small cell lung cancer. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.